Indian Immunologicals Ltd to launch 4 vaccines in next one year
Indian Immunologicals Ltd, a subsidiary of National Dairy Development Board will launch four vaccines in the next one year and will invest Rs 150 crore to set up a new manufacturing facility in Hyderabad.
The new facility will come up by the middle of next year near Hyderabad in an area of 50 acres and will produce both animal and human vaccines. At present, the company has two vaccine-manufacturing units in Ooty and Hyderabad. Pentavalent vaccine combines five different vaccines in one injection to protect against five diseases including Tetanus and Hepatitis B.
The company, which was created by National Dairy Development Board with the objective of making Foot and Mouth Disease (FMD) vaccines available for farmers at affordable prices and gradually expanded to other areas, clocked a sales turnover of Rs 271 crore in 2009-10. The company started with animal vaccines in 1982 and then started manufacturing human vaccines in the year 2000.
Venus Remedies to launch the world’s first once-a-day pain killer injection
Venus Remedies Ltd, amongst the prominent injectables manufacturer in Asia, is all set to launch the world's first once-a-day painkiller injectable in the country. The product aceclofenac OD has just bagged a patent from the Indian Patent office.
Aceclofenac is a NSAID (non steroidal anti inflammatory drug) used for the relief of acute as well as chronic pain and inflammation in rheumatoid arthritis, osteoarthritis, low back pain, ankylosing spondylitis, dental pain, post traumatic pain, gynecological pain and oncology pain.
"This novel formulation based on NDDS (Novel drug delivery system) technology starts its action instantly and gives immediate relief from acute pain. The drug will be effective for the next 24 hours as against the conventional daily dose of three injections of diclofenac given every 8 hr. It not only reduces the number of pricks but also drastically reduces the side effects associated with the use of NSAIDs," said Dr. Manu Chaudhary, Director, Venus Medicine Research Center, the R&D division of Venus Remedies.
Opioid based products or conventional NSAIDs being used currently for pain management are associated with side effects such as vomiting, nausea, abdominal distress. Aceclofenac is designed in such a way that the product is never released in super or sub therapeutic zones and hence is highly safe and practically free from side effects, said Dr. Chaudhary.
"We have very high aspirations from this product and hope to capture 10% market share in the early years of launch. Venus is already in talks with top global pharmaceutical companies for out licensing of this product," said Dr. Chaudhary.
The most prevalent forms of neuropathic pain in country includes neuralgia/fibromyalgia and lower back pain, with 16.3m and 15.9m cases respectively during 2008. Analgesics (narcotics and non–narcotics) account for 43% of the global pain management market, having generated revenues of $19.9bn in 2007, showing an annual growth of 15.2 %.
Venus Remedies Ltd is a research and development driven, pharmaceutical manufacturing company. Among the top 50 Indian Pharma companies of India, the company has out paced most Indian pharmaceutical companies in its growth and value creation over the past few years.
|
|
